FENNEC PHARMACEUTICALS INC. Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Fennec Pharmaceuticals Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2010 to Q3 2024.
  • Fennec Pharmaceuticals Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$5.74M, a 207% decline year-over-year.
  • Fennec Pharmaceuticals Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$1.13M, a 94.4% increase year-over-year.
  • Fennec Pharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$16M, a 32.3% increase from 2022.
  • Fennec Pharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$23.7M, a 36.7% decline from 2021.
  • Fennec Pharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$17.3M, a 4.21% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$1.13M -$5.74M -$3.87M -207% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-08
Q2 2024 $2.74M -$5.55M -$109K -2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-08
Q1 2024 $2.84M $12.8M +$18.9M Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-08
Q4 2023 -$16M -$2.68M +$4.18M +60.9% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-29
Q3 2023 -$20.2M -$1.87M +$6.22M +76.9% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-08
Q2 2023 -$26.4M -$5.44M -$372K -7.33% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-08
Q1 2023 -$26.1M -$6.05M -$2.36M -63.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-08
Q4 2022 -$23.7M -$6.86M -$2.43M -54.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-29
Q3 2022 -$21.3M -$8.09M -$3.9M -93.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$17.4M -$5.07M -$1.07M -26.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$16.3M -$3.7M +$1.04M +21.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 -$17.3M -$4.43M -$1.19M -36.7% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-29
Q3 2021 -$16.2M -$4.19M +$2.02M +32.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$18.2M -$4M +$844K +17.4% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-14
Q1 2021 -$19M -$4.73M -$907K -23.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-14
Q4 2020 -$18.1M -$3.24M +$372K +10.3% Oct 1, 2020 Dec 31, 2020 10-K 2022-02-28
Q3 2020 -$18.5M -$6.2M -$4.39M -243% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$14.1M -$4.85M -$115K -2.43% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-10
Q1 2020 -$14M -$3.83M -$1.2M -45.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-10
Q4 2019 -$12.8M -$3.61M -$626K -21% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-30
Q3 2019 -$12.1M -$1.81M +$940K +34.2% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 -$13.1M -$4.73M -$2.14M -82.8% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-16
Q1 2019 -$10.9M -$2.63M -$1.06M -67.5% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-16
Q4 2018 -$9.89M -$2.98M -$694K -30.3% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-14
Q3 2018 -$9.19M -$2.75M -$397K -16.9% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$8.8M -$2.59M -$989K -61.9% Apr 1, 2018 Jun 30, 2018 10-Q 2019-11-12
Q1 2018 -$7.81M -$1.57M -$762K -94.5% Jan 1, 2018 Mar 31, 2018 10-Q 2019-11-12
Q4 2017 -$7.05M -$2.29M -$1.15M -100% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-15
Q3 2017 -$5.9M -$2.35M -$1.85M -369% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q2 2017 -$4.05M -$1.6M -$874K -121% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-13
Q1 2017 -$3.18M -$806K -$386K -91.9% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-14
Q4 2016 -$2.79M -$1.14M -$603K -112% Oct 1, 2016 Dec 31, 2016 10-Q 2017-05-12
Q3 2016 -$2.19M -$502K -$379K -308% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-13
Q2 2016 -$1.81M -$724K -$551K -318% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-14
Q1 2016 -$1.26M -$420K -$597K -337% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-12
Q4 2015 -$659K -$540K -$1.93M -139% Oct 1, 2015 Dec 31, 2015 10-Q 2016-11-14
Q3 2015 $1.27M -$123K -$503K -132% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-14
Q2 2015 $1.77M -$173K +$577K +76.9% Apr 1, 2015 Jun 30, 2015 10-Q 2016-11-14
Q1 2015 $1.2M $177K +$3.37M Jan 1, 2015 Mar 31, 2015 10-Q 2016-11-14
Q4 2014 -$2.18M $1.39M +$276K +24.8% Oct 1, 2014 Dec 31, 2014 10-K 2016-03-28
Q3 2014 -$2.45M $380K +$2.15M Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-12
Q2 2014 -$4.6M -$750K -$7.36M -111% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-11
Q1 2014 $2.76M -$3.19M +$914K +22.2% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-15
Q4 2013 $1.85M $1.11M +$7.62M Oct 1, 2013 Dec 31, 2013 10-Q 2015-11-12
Q3 2013 -$5.78M -$1.77M -$1M -131% Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-13
Q2 2013 -$4.78M $6.61M +$7.21M Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-11
Q1 2013 -$12M -$4.11M -$6.82M -251% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-15
Q4 2012 -$5.16M -$6.51M -$10M -286% Oct 1, 2012 Dec 31, 2012 10-Q 2014-11-13
Q3 2012 $4.86M -$764K +$2.38M +75.7% Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-18
Q2 2012 $2.48M -$602K -$254K -73% Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-09
Q1 2012 $2.73M $2.72M -$1.95M -41.9% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-13
Q4 2011 $4.69M $3.51M Oct 1, 2011 Dec 31, 2011 10-Q 2014-11-13
Q3 2011 -$3.14M -$4.84M -286% Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-14
Q2 2011 -$348K +$2.22M +86.5% Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-13
Q1 2011 $4.67M Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-15
Q3 2010 $1.69M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-14
Q2 2010 -$2.57M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.